DALLAS, Nov. 11, 2021
/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical
stage biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that Lantern Pharma's abstract on
the effectiveness of LP-184 in glioblastoma multiforme (GBM)
regardless of MGMT status has been accepted as a virtual poster at
the upcoming 26th Society for Neuro-Oncology (SNO)
Annual Meeting, which is being held in person and virtually from
November 18-21, 2021. The abstract is
available online on the SNO website.
Abstract Title: LP-184, a novel alkylating agent, is
effective in Glioblastoma
Abstract ID: EXTH-16
Submission type: Adult
Abstract Tumor Type: Glial Tumors
Abstract Category: Preclinical Experimental Therapeutics
Poster Session Date & Time: Friday, November 19, 2021, 7:30 PM - 9.30 PM
EST
Presenter: Aditya Kulkarni, Ph.D., Lantern Pharma
The abstract submitted by Lantern Pharma and researchers at The
Kennedy Krieger Institute affiliated with Johns Hopkins School of Medicine describes work
demonstrating promising efficacy of LP-184 in multiple in vitro and
in vivo glioblastoma models. The abstract also highlights the
increased efficacy of LP-184 in MGMT unmethylated GBM, an area of
large unmet clinical need, as well as the predicted synthetic
lethality of LP-184 in GBM with DNA damage repair deficiencies such
as decreased expression of nucleotide excision repair components
ERCC3/6. The poster displays the favorable blood brain barrier
crossing properties of LP-184 evaluated in vivo, suggesting that
the maximum brain concentration achieved after a single intravenous
infusion of LP-184 in mice is greater than that required for growth
inhibition of sensitive GBM cells. These findings identify
LP-184 as a promising new alkylating agent and support its further
development for GBM therapy.
Electronic poster presentation files will be captured
electronically (in PDF) prior to the meeting and available on the
mobile meeting app, website and onsite. Accepted abstracts will be
published as a proceedings supplement in Neuro-Oncology, the
official journal of the SNO after the completion of the
meeting.
LP-184 is a small molecule drug candidate and next generation
acylfulvene that preferentially damages DNA in cancer cells that
overexpress certain biomarkers and is therefore lethal in tumors
that harbor mutations in DNA repair pathways or have deficiency in
these pathways because of low expression of genes required for DNA
repair. LP-184 is being developed for several targeted central
nervous system cancer indications, including glioblastoma. LP-184
has recently been granted Orphan Drug Designation by the U.S. Food
and Drug Administration for the treatment of malignant gliomas, as
well as pancreatic cancer.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
eight disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
About RADR®
RADR® or Response Algorithm for Drug
Positioning & Rescue, is Lantern's proprietary
integrated A.I. platform for large-scale biomarker and drug-tumor
interaction data analytics that leverages machine-learning.
RADR® is used to provide mechanistic insights about
drug-tumor interactions, predict the potential response of cancer
types and subtypes to existing drugs and drug candidates, and
uncover patient groups that may respond to potential therapies
being developed by Lantern and its collaborators.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; our research and development efforts
of our internal drug discovery programs and the utilization of our
RADR® platform to streamline the drug development
process; our intention to leverage artificial intelligence, machine
learning and genomic data to streamline and transform the pace,
risk and cost of oncology drug discovery and development and to
identify patient populations that would likely respond to a drug
candidate; estimates regarding potential markets and potential
market sizes; sales estimates for our drug candidates and our plans
to discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates ourselves or
in collaboration with others. Any statements that are not
statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of
our collaborators may not be successful, (iii) the risk that none
of our product candidates has received FDA marketing approval, and
we may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov.
Given these risks and uncertainties, we can give no assurances that
our forward-looking statements will prove to be accurate, or that
any other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
CONTACT:
Investor Relations
David
Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
212-671-1021
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-abstract-on-effectiveness-of-lp-184-in-glioblastoma-accepted-for-presentation-at-the-society-for-neuro-oncology-2021-annual-meeting-301422140.html
SOURCE Lantern Pharma